Shares in ophthalmology specialist Bausch + Lomb (B+L ... firms had partnered on a potential bid for B+L, which sells contact lenses as well as ophthalmic pharmaceuticals, intraocular lenses ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Hold rating on Bausch + Lomb Corporation (BLCO – Research Report), ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against the other best ...

Young nearsighted kids who wear bifocal contact lenses that slow uncoordinated eye growth do not lose the benefits of the treatment once they stop wearing the lenses, new research shows.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

Contact lens company Bausch + Lomb is taking bold action to address a unique yet growing issue: contact lens and packaging waste. Through its innovative ...

Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release.Using ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union ...

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...